Glycaemic status and cardiovascular disease in type 2 diabetes mellitus: Re-visiting glycated haemoglobin targets for cardiovascular disease prevention

Sherita H. Golden, Elizabeth Selvin, Kayla E. Cunningham

Research output: Contribution to journalReview articlepeer-review

Abstract

Cardiovascular disease (CVD) is the leading cause of death among people with type 2 diabetes. Recent attention has focused on chronic hyperglycaemia as an additional risk factor in people with diabetes since their excess CVD risk is not entirely explained by traditional cardiovascular risk factors. Clinical trials of intensive glucose control to reduce CVD events have been equivocal, but recent epidemiological studies have shown that HbAlc, a measure of chronic hyperglycaemia, predicts incident cardiovascular events. This review, which focuses on type 2 diabetes, summarizes (i) the epidemiological literature examining the relation between glycaemic status, as assessed by glycated haemoglobin (HbAlc) and CVD, (ii) the controversy regarding treatment goals for HbAlc in terms of preventing microvascular disease vs. macrovascular disease and (iii) on-going clinical trials of intensive glycaemic control for CVD prevention.

Original languageEnglish (US)
Pages (from-to)792-798
Number of pages7
JournalDiabetes, Obesity and Metabolism
Volume9
Issue number6
DOIs
StatePublished - Nov 2007

Keywords

  • Cardiovascular disease
  • Diabetes mellitus
  • Glycated haemoglobin

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Glycaemic status and cardiovascular disease in type 2 diabetes mellitus: Re-visiting glycated haemoglobin targets for cardiovascular disease prevention'. Together they form a unique fingerprint.

Cite this